Márcio Borges Sá

Márcio Borges Sá

Auto-generated profile, based on publicly available information

Márcio Borges Sá

Multidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2012 in Critical Care
Verified
Journal Article
Open access
PDF file
RMRosario Molina
Rosario Molina
TBTeresa Bernal
Teresa Bernal
MBMarcio Borges
Marcio Borges
RZRafael Zaragoza
Rafael Zaragoza
JBJuan Bonastre
Juan Bonastre
TIthe EMEHU study investigators
the EMEHU study investigators
Introduction: Hematology patients admitted to the ICU frequently experience respiratory failure and require mechanical ventilation. Noninvasive mechanical ventilation (NIMV) may decrease the risk of intubation, but NIMV failure poses its own risks. Methods: To establish the impact of ventilatory management and NIMV failure on outcome, data from a prospective, multicenter, observational study were analyzed. All hematology patients admitted to one of the 34 participating ICUs in a 17-month period were followed up. Data on demographics, diagnosis, severity, organ failure, and supportive therapies were recorded. A logistic regression analysis was done to evaluate the risk factors associated with death and NIVM failure. Results: Of 450 patients, 300 required ventilatory support. A diagnosis of congestive heart failure and the initial use of NIMV significantly improved survival, whereas APACHE II score, allogeneic transplantation, and NIMV failure increased the risk of death. The risk factors associated with NIMV success were age, congestive heart failure, and bacteremia. Patients with NIMV failure experienced a more severe respiratory impairment than did those electively intubated. Conclusions: NIMV improves the outcome of hematology patients with respiratory insufficiency, but NIMV failure may have the opposite effect. A careful selection of patients with rapidly reversible causes of respiratory failure may increase NIMV success.

24 July 2020 in Microorganisms
Verified
Journal Article
Open access
PDF file
RRRoberto De La Rica
Roberto De La Rica
MBMarcio Borges
Marcio Borges
MAMaria Aranda
Maria Aranda
ACAlberto del Castillo
Alberto del Castillo
Antonia Socias MirAntonia Socias Mir
Antonia Socias Mir
MGMarta Gonzalez-Freire
Marta Gonzalez-Freire
There is limited information available describing the clinical and epidemiological features of Spanish patients requiring hospitalization for coronavirus disease 2019 (COVID-19). In this observational study, we aimed to describe the clinical characteristics and epidemiological features of severe (non-ICU) and critically patients (ICU) with COVID-19 at triage, prior to hospitalization. Forty-eight patients (27 non-ICU and 21 ICU) with positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were analyzed (mean age, 66 years, [range, 33–88 years]; 67% males). There were no differences in age or sex among groups. Initial symptoms included fever (100%), coughing (85%), dyspnea (76%), diarrhea (42%) and asthenia (21%). ICU patients had a higher prevalence of dyspnea compared to non-ICU patients (95% vs. 61%, p = 0.022). ICU-patients had lymphopenia as well as hypoalbuminemia. Lactate dehydrogenase (LDH), C-reactive protein (CRP), and procalcitonin were significantly higher in ICU patients compared to non-ICU (p < 0.001). Lower albumin levels were associated with poor prognosis measured as longer hospital length (r = −0.472, p < 0.001) and mortality (r = −0.424, p = 0.003). As of 28 April 2020, 10 patients (8 ICU and 2 non-ICU) have died (21% mortality), and while 100% of the non-ICU patients have been discharged, 33% of the ICU patients still remained hospitalized (5 in ICU and 2 had been transferred to ward). Critically ill patients with COVID-19 present lymphopenia, hypoalbuminemia and high levels of inflammation.

30 December 2013 in Critical Care
Verified
Journal Article
Open access
PDF file
TBTeresa Bernal
Teresa Bernal
EPEstefanía V Pardavila
Estefanía V Pardavila
JBJuan Bonastre
Juan Bonastre
IJIsidro Jarque
Isidro Jarque
MBMarcio Borges
Marcio Borges
GAGuillermo M Albaiceta
Guillermo M Albaiceta
Introduction: Although the survival rates of hematological patients admitted to the ICU are improving, little is known about the long-term outcome. Our objective was to identify factors related to long-term outcome in hematological patients after ICU discharge. Methods: A prospective, observational study was carried out in seven centers in Spain. From an initial sample of 161 hematological patients admitted to one of the participating ICUs during the study period, 62 were discharged alive and followed for a median time of 23 (1 to 54) months. Univariate and multivariate analysis were performed to identify the factors related to long term-survival. Finally, variables that influence the continuation of the scheduled therapy for the hematological disease were studied. Results: Mortality after ICU discharge was 61%, with a median survival of 18 (1 to 54) months. In the multivariate analysis, an Eastern Cooperative Oncology Group score (ECOG) >2 at ICU discharge (Hazard ratio 11.15 (4.626 to 26.872)), relapse of the hematological disease (Hazard ratio 9.738 (3.804 to 24.93)) and discontinuation of the planned treatment for the hematological disease (Hazard ratio 4.349 (1.286 to 14.705)) were independently related to mortality. Absence of stem cell transplantation, high ECOG and high Acute Physiology and Chronic Health Evaluation II (APACHE II) scores decreased the probability of receiving the planned therapy for the hematological malignancy. Conclusions: Both ICU care and post-ICU management determine the long-term outcome of hematological patients who are discharged alive from the ICU.

30 November 2008 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
MSMárcio Borges Sá
Márcio Borges Sá
RZRafael Zaragoza
Rafael Zaragoza


1 April 2012 in Revista Iberoamericana de Micologia
Verified
Journal Article
Closed access
MBMarcio Borges-Sá
Marcio Borges-Sá
MAMaría Aranda-Pérez
María Aranda-Pérez